SCM Pharma makes an appointment

Paul Thomas joins CDMO as a non-executive director

SCM Pharma, a specialist contract development and manufacturing organisation (CDMO), has appointed a new director to bolster its senior team’s expertise and support its ongoing expansion.

Qualified Person (QP) Paul Thomas has joined the UK-based company as a non-executive director and brings a wealth of sterile manufacturing, technical and commercial experience gained over 25 years in the sector working for companies such as Warner Lambert, Penn Pharma and Nycomed Amersham (now GE).

A trained chemist and QP, Thomas has worked across many aspects of drug development and manufacturing during his career including analytical, production, quality and senior commercial roles across the world.

You may also like

Manufacturing

Shire buys assets of SCM Pharma

Confirms that 80 jobs are safeguarded at Northumberland-based company
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

HAPI capacity reaches an all-time high

While today’s drugs are more targeted and effective, they bring with them production issues of sterility and higher potency. Susan Birks reports on how the contract manufacturing market has responded to the growing demand for specialist high potency and sterile services
You need to be a subscriber to read this article.
Click here to find out more.
Containment

Handle with care – high potency APIs

Contract manufacturer SCM Pharma, which handles small volume runs of cytotoxic powders and liquids for several clients, outlines the basic containment and cleaning requirements for ensuring worker safety and product purity
Manufacturing

SCM\'s Prudhoe facility gains FDA approval

UK CDMO supports BTG for commercial launch of varicose veins treatment
Manufacturing

SCM Pharma gains MHRA approval for commercial facility

The site will be used for the supply of licensed commercial products and to complement its clinical manufacturing facility
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The changing landscape of clinical trial manufacturing

With regulation changes, the death of the blockbuster, focus on personalised medicines and less R&D spend than ever before, the clinical trial manufacturing landscape has undergone many changes. SCM Pharma’s Dianne Sharp reviews the sector and outlines what companies of the future could look like
Manufacturing

SCM supports BTG in Varisolve scale-up

CDMO has previously been providing clinical development consultancy for varicose vein treatment
Subscribe now